Not yet recruiting
Treatment Strategy for Patients With RA-ILD
NCT07643038· Phase 4· Chinese SLE Treatment And Research Group· Source
Not yet recruiting
Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
NCT07745257· Phase 2· Sun Yat-sen University· Source
Recruiting
Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)
NCT07567625· Harbin Medical University· Source
Recruiting
Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension
NCT07607275· Phase 4· Beijing Anzhen Hospital· Source
Recruiting
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
NCT07389733· Phase 1/2· Shandong Suncadia Medicine Co., Ltd.· Source
Recruiting
Efficacy of Montelukast on STEMl Patients
NCT07320625· Phase 3· Shanghai Zhongshan Hospital· Source
Recruiting
Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial
NCT07402525· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source
Recruiting
Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients
NCT07266116· Phase 1/2· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Recruiting
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065· Phase 2· Guangzhou Lupeng Pharmaceutical Company LTD.· Source
Recruiting
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
NCT07083154· Phase 3· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Source
Recruiting
Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer
NCT07285382· Phase 2· wanghaibo· Source
Recruiting
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
NCT06862869· Hoffmann-La Roche· Source
Recruiting
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
NCT06854445· Phase 2· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Not yet recruiting
Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study
NCT06820762· Phase 2· The Second Affiliated Hospital of Dalian Medical University· Source
Recruiting
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
NCT07673029· Phase 3· GeneQuantum Healthcare (Suzhou) Co., Ltd.· Source
Active, not recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06711900· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Recruiting
Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
NCT06760273· Shanghai Pulmonary Hospital, Shanghai, China· Source
Active, not recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06448312· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Recruiting
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
NCT06079983· Phase 3· Jiangsu Alphamab Biopharmaceuticals Co., Ltd· Source
Recruiting
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
NCT05410925· Phase 4· The First Affiliated Hospital with Nanjing Medical University· Source
Recruiting
Stage II/III Colorectal Cancer Recurrence
NCT06314958· City of Hope Medical Center· Source
Recruiting
Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks
NCT05230017· Peking Union Medical College Hospital· Source
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846· Phase 3· AbbVie· Source
Active, not recruiting
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04384484· Phase 3· ADC Therapeutics S.A.· Source